Major advances in early detection and novel treatment strategies in the development of prostate cancer in past years are mainly due to the execution of large-scale profiling omics projects such as genomics, epigenomics, transcriptomics/epi-transcriptomic, proteomics, metabolomics. However, the discovery of efficient and accountable biomarkers in earlier diagnosis, prognosis evaluation and new therapeutics targets in cancer patients are still urgently needed. Particularly, newer strategies against cancer metastasis and treatment resistance are two major challenging topics in front of clinical oncologists and translational/basic cancer researchers. Additionally, the connections of the genetic/epigenetic sequencing findings to cancer biology functional analysis including clinical applicable unique signaling pathways through novel in vitro and in vivo models needs more exploration.
Identification of potential biomarker/biomarker panels with clinical application for earlier diagnosis, disease aggressive progression monitoring including classic treatment resistance and metastasis development as well as innovative therapeutic targets with omics profiling technologies, which would include but not limited to next-generation sequencing, RNA sequencing, exome sequencing, epigenetic including methylation sequencing, epi-transcriptome sequencing including micro-RNA and non-coding RNA, the analysis of SNP, mutation, proteomics, metabolomics, immunology targets as well as the associate cancer biology and unique signaling pathways function assays. The ultimate goal is to localize the clinically functional molecular targets in prostate cancer.
This Research Topic welcomes Reviews and Original research covering all the aspects of innovative biomarkers and therapies in prostate cancer. Topics include but are not limited to:
-In vitro and in vivo cancer therapeutic responses
-Targeted identification of novel therapeutic targets
-Evaluation of novel diagnosis and prognosis markers based on the cancer genomics/epigenomics and biology analysis (genetic/epigenetic/transcriptomics/proteomics/metabolomics profiling including the novel molecular/pathological/imaging techniques in early diagnosis)
-Development of in vitro and in vivo carcinogenesis models for the discovery of cancer risk factors and innovative anti-cancer drugs, cancer biology assay for molecular mechanism of aggressive disease progression and other preclinical model studies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Major advances in early detection and novel treatment strategies in the development of prostate cancer in past years are mainly due to the execution of large-scale profiling omics projects such as genomics, epigenomics, transcriptomics/epi-transcriptomic, proteomics, metabolomics. However, the discovery of efficient and accountable biomarkers in earlier diagnosis, prognosis evaluation and new therapeutics targets in cancer patients are still urgently needed. Particularly, newer strategies against cancer metastasis and treatment resistance are two major challenging topics in front of clinical oncologists and translational/basic cancer researchers. Additionally, the connections of the genetic/epigenetic sequencing findings to cancer biology functional analysis including clinical applicable unique signaling pathways through novel in vitro and in vivo models needs more exploration.
Identification of potential biomarker/biomarker panels with clinical application for earlier diagnosis, disease aggressive progression monitoring including classic treatment resistance and metastasis development as well as innovative therapeutic targets with omics profiling technologies, which would include but not limited to next-generation sequencing, RNA sequencing, exome sequencing, epigenetic including methylation sequencing, epi-transcriptome sequencing including micro-RNA and non-coding RNA, the analysis of SNP, mutation, proteomics, metabolomics, immunology targets as well as the associate cancer biology and unique signaling pathways function assays. The ultimate goal is to localize the clinically functional molecular targets in prostate cancer.
This Research Topic welcomes Reviews and Original research covering all the aspects of innovative biomarkers and therapies in prostate cancer. Topics include but are not limited to:
-In vitro and in vivo cancer therapeutic responses
-Targeted identification of novel therapeutic targets
-Evaluation of novel diagnosis and prognosis markers based on the cancer genomics/epigenomics and biology analysis (genetic/epigenetic/transcriptomics/proteomics/metabolomics profiling including the novel molecular/pathological/imaging techniques in early diagnosis)
-Development of in vitro and in vivo carcinogenesis models for the discovery of cancer risk factors and innovative anti-cancer drugs, cancer biology assay for molecular mechanism of aggressive disease progression and other preclinical model studies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
